Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
[Key factors in design of case report form].

Yao xue xue bao = Acta pharmaceutica Sinica

Fu HJ, Luo XX.
PMID: 26911041
Yao Xue Xue Bao. 2015 Nov;50(11):1452-5.

Case report form (CRF) is a key document for data collection in clinical trials. A well-designed CRF is required for database construction, data accuracy, data query/cleaning, CRF completion and statistical analysis. A well-defined process or SOP should be in...

Cite
Fu HJ, Luo XX. [Key factors in design of case report form]. Yao Xue Xue Bao. 2015;50(11):1452-5
Fu, H. J., & Luo, X. X. (2015). [Key factors in design of case report form]. Yao xue xue bao = Acta pharmaceutica Sinica, 50(11), 1452-5.
Fu, Hai-jun, and Luo, Xiao-xia. "[Key factors in design of case report form]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 50,11 (2015): 1452-5.
Fu HJ, Luo XX. [Key factors in design of case report form]. Yao Xue Xue Bao. 2015 Nov;50(11):1452-5. Chinese. PMID: 26911041.
Copy Download .nbib Format: NLM
[Data quality in clinical trials: the role of blind review].

Yao xue xue bao = Acta pharmaceutica Sinica

Yu YP, Yao C.
PMID: 26911051
Yao Xue Xue Bao. 2015 Nov;50(11):1498-501.

Blind review is one of the most important milestones in clinical trials, which connects data management process to statistical analysis. During blind review, data quality should be reviewed and assessed on both data management and statistical aspects. The primary...

Cite
Yu YP, Yao C. [Data quality in clinical trials: the role of blind review]. Yao Xue Xue Bao. 2015;50(11):1498-501
Yu, Y. P., & Yao, C. (2015). [Data quality in clinical trials: the role of blind review]. Yao xue xue bao = Acta pharmaceutica Sinica, 50(11), 1498-501.
Yu, Yong-pei, and Yao, Chen. "[Data quality in clinical trials: the role of blind review]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 50,11 (2015): 1498-501.
Yu YP, Yao C. [Data quality in clinical trials: the role of blind review]. Yao Xue Xue Bao. 2015 Nov;50(11):1498-501. Chinese. PMID: 26911051.
Copy Download .nbib Format: NLM
[Chemical constituents of Ligularia duciformis].

Yao xue xue bao = Acta pharmaceutica Sinica

Fu KZ, Yu NJ, Zhang Y, Zhao YM.
PMID: 17702399
Yao Xue Xue Bao. 2007 Jun;42(6):621-4.

Ligularia duciformis is a plant of the Ligularia genus (Compositae) which has been reported to have therapeutic effects of treating diseases such as bronchitis and coughing. In order to find out the bioactive components, the 85% ethanol extract of...

Cite
Fu KZ, Yu NJ, Zhang Y, et al. [Chemical constituents of Ligularia duciformis]. Yao Xue Xue Bao. 2007;42(6):621-4
Fu, K. Z., Yu, N. J., Zhang, Y., & Zhao, Y. M. (2007). [Chemical constituents of Ligularia duciformis]. Yao xue xue bao = Acta pharmaceutica Sinica, 42(6), 621-4.
Fu, Kai-Zhou, et al. "[Chemical constituents of Ligularia duciformis]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 42,6 (2007): 621-4.
Fu KZ, Yu NJ, Zhang Y, Zhao YM. [Chemical constituents of Ligularia duciformis]. Yao Xue Xue Bao. 2007 Jun;42(6):621-4. Chinese. PMID: 17702399.
Copy Download .nbib Format: NLM
[Advances in pharmacological studies of Panax notoginseng saponins on brain ischemia-reperfusion injury].

Yao xue xue bao = Acta pharmaceutica Sinica

Yang PF, Song XY, Chen NH.
PMID: 29896951
Yao Xue Xue Bao. 2016 Jul;51(7):1039-46.

Sanqi in Chinese herbal medicine is the root and rhizoma of Panax notoginseng (Burk.) F.H. Chen, which belongs to genus Panax in the Araliaceae family and is widely used as a tonic medicine in the traditional Chinese medicine. The...

Cite
Yang PF, Song XY, Chen NH. [Advances in pharmacological studies of Panax notoginseng saponins on brain ischemia-reperfusion injury]. Yao Xue Xue Bao. 2016;51(7):1039-46
Yang, P. F., Song, X. Y., & Chen, N. H. (2016). [Advances in pharmacological studies of Panax notoginseng saponins on brain ischemia-reperfusion injury]. Yao xue xue bao = Acta pharmaceutica Sinica, 51(7), 1039-46.
Yang, Peng-fei, et al. "[Advances in pharmacological studies of Panax notoginseng saponins on brain ischemia-reperfusion injury]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 51,7 (2016): 1039-46.
Yang PF, Song XY, Chen NH. [Advances in pharmacological studies of Panax notoginseng saponins on brain ischemia-reperfusion injury]. Yao Xue Xue Bao. 2016 Jul;51(7):1039-46. Chinese. PMID: 29896951.
Copy Download .nbib Format: NLM
[Concise analysis for innovation of pioneering and follow-on drugs].

Yao xue xue bao = Acta pharmaceutica Sinica

Guo ZR.
PMID: 29897709
Yao Xue Xue Bao. 2016 Aug;51(8):1179-84.

More attention has been paid to the pioneering drug innovation since the new millennium, while the creation space of fast-followed drugs is shrinking due to the serious risks observed in the clinical phases following marketing. Innovative drug discovery aiming...

Cite
Guo ZR. [Concise analysis for innovation of pioneering and follow-on drugs]. Yao Xue Xue Bao. 2016;51(8):1179-84
Guo, Z. R. (2016). [Concise analysis for innovation of pioneering and follow-on drugs]. Yao xue xue bao = Acta pharmaceutica Sinica, 51(8), 1179-84.
Guo, Zong-ru. "[Concise analysis for innovation of pioneering and follow-on drugs]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 51,8 (2016): 1179-84.
Guo ZR. [Concise analysis for innovation of pioneering and follow-on drugs]. Yao Xue Xue Bao. 2016 Aug;51(8):1179-84. Chinese. PMID: 29897709.
Copy Download .nbib Format: NLM
Challenges in Drug Discovery for Thiazolidinedione Substitute.

Yao xue xue bao = Acta pharmaceutica Sinica

Ye J.
PMID: 22427718
Yao Xue Xue Bao. 2011 Oct 01;1(3):137-142. doi: 10.1016/j.apsb.2011.06.011.

Thiazolidinedione (TZD) is a powerful insulin sensitizer in the treatment of type 2 diabetes. It acts as a ligand to the nuclear receptor PPARĪ³ (peroxisome proliferator-activated receptor-gamma) and induces transcription of PPARĪ³ responsive genes. TZD controls lipid synthesis and...

Cite
Ye J. Challenges in Drug Discovery for Thiazolidinedione Substitute. Yao Xue Xue Bao. 2011;1(3):137-142doi: 10.1016/j.apsb.2011.06.011.
Ye, J. (2011). Challenges in Drug Discovery for Thiazolidinedione Substitute. Yao xue xue bao = Acta pharmaceutica Sinica, 1(3), 137-142. https://doi.org/10.1016/j.apsb.2011.06.011
Ye, Jianping. "Challenges in Drug Discovery for Thiazolidinedione Substitute." Yao xue xue bao = Acta pharmaceutica Sinica vol. 1,3 (2011): 137-142. doi: https://doi.org/10.1016/j.apsb.2011.06.011
Ye J. Challenges in Drug Discovery for Thiazolidinedione Substitute. Yao Xue Xue Bao. 2011 Oct 01;1(3):137-142. doi: 10.1016/j.apsb.2011.06.011. PMID: 22427718; PMCID: PMC3302162.
Copy Download .nbib Format: NLM
[PROGRESS ON PENICILLIN ANTIBIOTICS].

Yao xue xue bao = Acta pharmaceutica Sinica

CHEN W.
PMID: 14075917
Yao Xue Xue Bao. 1962 Jul;9:439-52.

No abstract available.

Cite
CHEN W. [PROGRESS ON PENICILLIN ANTIBIOTICS]. Yao Xue Xue Bao. 1962;9:439-52
CHEN, W. (1962). [PROGRESS ON PENICILLIN ANTIBIOTICS]. Yao xue xue bao = Acta pharmaceutica Sinica, 9439-52.
CHEN, W. "[PROGRESS ON PENICILLIN ANTIBIOTICS]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 9 (1962): 439-52.
CHEN W. [PROGRESS ON PENICILLIN ANTIBIOTICS]. Yao Xue Xue Bao. 1962 Jul;9:439-52. Chinese. PMID: 14075917.
Copy Download .nbib Format: NLM
[The application of enzyme-sensitive activatable cell-penetrating peptides to targeted delivery system].

Yao xue xue bao = Acta pharmaceutica Sinica

He F, Cao L, Zhang XJ, Xiang B, Cao DY, Qi XR.
PMID: 25975019
Yao Xue Xue Bao. 2015 Feb;50(2):141-7.

Cell-penetrating peptides (CPPs) offer a non-selective and receptor-independent mode to promote cellular uptake. Although the non-specificity of CPP-mediated internalization allows this approach applicable to a wide range of tumor types potentially, their universality is a significant obstacle to their...

Cite
He F, Cao L, Zhang XJ, et al. [The application of enzyme-sensitive activatable cell-penetrating peptides to targeted delivery system]. Yao Xue Xue Bao. 2015;50(2):141-7
He, F., Cao, L., Zhang, X. J., Xiang, B., Cao, D. Y., & Qi, X. R. (2015). [The application of enzyme-sensitive activatable cell-penetrating peptides to targeted delivery system]. Yao xue xue bao = Acta pharmaceutica Sinica, 50(2), 141-7.
He, Fan, et al. "[The application of enzyme-sensitive activatable cell-penetrating peptides to targeted delivery system]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 50,2 (2015): 141-7.
He F, Cao L, Zhang XJ, Xiang B, Cao DY, Qi XR. [The application of enzyme-sensitive activatable cell-penetrating peptides to targeted delivery system]. Yao Xue Xue Bao. 2015 Feb;50(2):141-7. Chinese. PMID: 25975019.
Copy Download .nbib Format: NLM
[Process and method for CDISC-based CRF annotation].

Yao xue xue bao = Acta pharmaceutica Sinica

Wang HW, Deng YZ, Liu D.
PMID: 26911046
Yao Xue Xue Bao. 2015 Nov;50(11):1474-9.

A CDASH-based CRF annotation plays an important role in database setup and data verification. The STDM-based CRF annotation is also one of the essential documents when the package of clinical trial data is submitted to the regulatory authority. This...

Cite
Wang HW, Deng YZ, Liu D. [Process and method for CDISC-based CRF annotation]. Yao Xue Xue Bao. 2015;50(11):1474-9
Wang, H. W., Deng, Y. Z., & Liu, D. (2015). [Process and method for CDISC-based CRF annotation]. Yao xue xue bao = Acta pharmaceutica Sinica, 50(11), 1474-9.
Wang, Hong-wei, et al. "[Process and method for CDISC-based CRF annotation]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 50,11 (2015): 1474-9.
Wang HW, Deng YZ, Liu D. [Process and method for CDISC-based CRF annotation]. Yao Xue Xue Bao. 2015 Nov;50(11):1474-9. Chinese. PMID: 26911046.
Copy Download .nbib Format: NLM
[Master documentation and records in the clinical data management].

Yao xue xue bao = Acta pharmaceutica Sinica

Sun HL, Xu G, Li W, Wei ZH, Ding L.
PMID: 26911025
Yao Xue Xue Bao. 2015 Nov;50(11):1365-6.

This list of clincal data management documentation is to ensure standardized and adequate archival of trial documents and records in clinical data management, which is applicable to all of phase I-IV clinical trials.

Cite
Sun HL, Xu G, Li W, et al. [Master documentation and records in the clinical data management]. Yao Xue Xue Bao. 2015;50(11):1365-6
Sun, H. L., Xu, G., Li, W., Wei, Z. H., & Ding, L. (2015). [Master documentation and records in the clinical data management]. Yao xue xue bao = Acta pharmaceutica Sinica, 50(11), 1365-6.
Sun, Hua-long, et al. "[Master documentation and records in the clinical data management]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 50,11 (2015): 1365-6.
Sun HL, Xu G, Li W, Wei ZH, Ding L. [Master documentation and records in the clinical data management]. Yao Xue Xue Bao. 2015 Nov;50(11):1365-6. Chinese. PMID: 26911025.
Copy Download .nbib Format: NLM
[Computational chemistry in structure-based drug design].

Yao xue xue bao = Acta pharmaceutica Sinica

Cao R, Li W, Sun HZ, Zhou Y, Huang N.
PMID: 24133970
Yao Xue Xue Bao. 2013 Jul;48(7):1041-52.

Today, the understanding of the sequence and structure of biologically relevant targets is growing rapidly and researchers from many disciplines, physics and computational science in particular, are making significant contributions to modern biology and drug discovery. However, it remains...

Cite
Cao R, Li W, Sun HZ, et al. [Computational chemistry in structure-based drug design]. Yao Xue Xue Bao. 2013;48(7):1041-52
Cao, R., Li, W., Sun, H. Z., Zhou, Y., & Huang, N. (2013). [Computational chemistry in structure-based drug design]. Yao xue xue bao = Acta pharmaceutica Sinica, 48(7), 1041-52.
Cao, Ran, et al. "[Computational chemistry in structure-based drug design]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 48,7 (2013): 1041-52.
Cao R, Li W, Sun HZ, Zhou Y, Huang N. [Computational chemistry in structure-based drug design]. Yao Xue Xue Bao. 2013 Jul;48(7):1041-52. Chinese. PMID: 24133970.
Copy Download .nbib Format: NLM
[Announcement of retraction].

Yao xue xue bao = Acta pharmaceutica Sinica

[No authors listed]
PMID: 19306522
Yao Xue Xue Bao. 2008 Mar;43(3):322.

No abstract available.

Cite
[Announcement of retraction]. Yao Xue Xue Bao. 2008;43(3):322
(2008). [Announcement of retraction]. Yao xue xue bao = Acta pharmaceutica Sinica, 43(3), 322.
"[Announcement of retraction]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 43,3 (2008): 322.
[Announcement of retraction]. Yao Xue Xue Bao. 2008 Mar;43(3):322. Chinese. PMID: 19306522.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries